title: Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation.
abstract: Serum thymic factor (FTS), a thymic peptide hormone, has been reported to attenuate the bleomycin-induced pulmonary injury and also experimental pancreatitis and diabetes. In the present study, we investigated the effect of FTS on cis-diamminedichloroplatinum II (cisplatin)-induced nephrotoxicity. We have already demonstrated that cephaloridine, a nephrotoxic antibiotic, leads to extracellular signal-regulated protein kinase (ERK) activation in the rat kidney, which probably contributes to cephaloridine-induced renal dysfunction. The aim of this study was to examine the effect of cisplatin on ERK activation in the rat kidney and also the effect of FTS on cisplatin-induced nephrotoxicity in rats. In vitro treatment of LLC-PK1 cells with FTS significantly ameliorated cisplatin-induced cell injury. Treatment of rats with intravenous cisplatin for 3 days markedly induced renal dysfunction and increased platinum contents in the kidney cortex. An increase in pERK was detected in the nuclear fraction prepared from the rat kidney cortex from days 1 to 3 after injection of cisplatin. FTS suppressed cisplatin-induced renal dysfunction and ERK activation in the kidney. FTS did not influence any Pt contents in the kidney after cisplatin administration. FTS has been shown to enhance the in vivo expression of heat shock protein (HSP) 70 in the kidney cortex. The beneficial role of FTS against cisplatin nephrotoxicity may be mediated in part by HSP70, as suggested by its up-regulation in the kidney cortex treated with FTS alone. Our results suggest that FTS participates in protection from cisplatin-induced nephrotoxicity by suppressing ERK activation caused by cisplatin.
authors.affiliation: Division of Pharmacology, Osaka University of Pharmaceutical Sciences, Nasahara, Takatsuki, Osaka 569-1094, Japan. kohda@gly.oups.ac.jp
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kohda
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Kawai
authors.forename: Noriaki
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Matsunaga
authors.forename: Hiromi
authors.initials: H
authors.lastname: Aiga
authors.forename: Akira
authors.initials: A
authors.lastname: Awaya
authors.forename: Munekazu
authors.initials: M
authors.lastname: Gemba
mesh_terms: D000818:Animals; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D002945:Cisplatin / Q000633:toxicity*; D004789:Enzyme Activation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D010766:Phosphorylation; D051381:Rats; D013552:Swine; D013935:Thymic Factor, Circulating / Q000494:pharmacology*
chemical_list: D018840:HSP70 Heat-Shock Proteins; D013935:Thymic Factor, Circulating; D048049:Extracellular Signal-Regulated MAP Kinases; D002945:Cisplatin